A structured approach for identifying disease analogs for pulmonary arterial hypertension.

IF 2.9 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Journal of managed care & specialty pharmacy Pub Date : 2025-09-01 Epub Date: 2025-07-31 DOI:10.18553/jmcp.2025.24354

Karim El-Kersh, Nadine Zawadzki, Anna Watzker, Shurui Zhang, Dhruv Dalal, Dominik Lautsch, Jason Shafrin

引用次数: 0

Abstract

Drug manufacturers often use disease analogs to describe diseases-particularly rare diseases-to payers, policymakers, and stakeholders. However, these comparisons are typically anecdotal. We propose a 4-step, systematic approach to identify disease analogs based on prespecified metrics and apply it to a rare disease, pulmonary arterial hypertension (PAH), as a case study. When there is limited knowledge of a rare disease, such as PAH, the application of the systematic disease analog approach presented can help managed care pharmacists leverage their existing knowledge and perspectives applied to other conditions to inform coverage, tier placement, and pricing decisions.

查看原文本刊更多论文

鉴别肺动脉高压疾病类似物的结构化方法。

药品制造商经常使用疾病类似物来描述疾病，特别是罕见疾病，以供付款人、政策制定者和利益相关者使用。然而，这些比较通常是道听途说。我们提出了一种基于预先指定指标的4步系统方法来识别疾病类似物，并将其应用于一种罕见疾病，肺动脉高压（PAH），作为案例研究。当对罕见疾病（如多环芳烃）的了解有限时，所提出的系统疾病模拟方法的应用可以帮助管理式护理药剂师利用他们现有的知识和观点应用于其他情况，以告知覆盖范围、分层安排和定价决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of managed care & specialty pharmacy Health Professions-Pharmacy

CiteScore

3.50

自引率

4.80%

发文量

131

期刊介绍： JMCP welcomes research studies conducted outside of the United States that are relevant to our readership. Our audience is primarily concerned with designing policies of formulary coverage, health benefit design, and pharmaceutical programs that are based on evidence from large populations of people. Studies of pharmacist interventions conducted outside the United States that have already been extensively studied within the United States and studies of small sample sizes in non-managed care environments outside of the United States (e.g., hospitals or community pharmacies) are generally of low interest to our readership. However, studies of health outcomes and costs assessed in large populations that provide evidence for formulary coverage, health benefit design, and pharmaceutical programs are of high interest to JMCP’s readership.